Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals
Sana, ESSA Pharma, Spero Reveal Strategic Shifts
Public Company Edition: Syndax received all $350m from its royalty financing up front, while KalVista got $100m initially out of up to $179m. Also, Vera, EyePoint and Eledon grossed $300m, $161m and $85m in follow-on offerings, while Neurogene raised $200m in a private placement.